BioSpace News Archive

Vedanta Biosciences, today announced the presentation of expanded, long-term positive data from its Phase 1a/1b study of VE303, the Company’s lead, orally-administered live biotherapeutic product (LBP) candidate for recurrent Clostridium difficile infection (rCDI).

Smart Meter, an innovative diabetes management data, technology and solutions company, today announced a strategic agreement with AmeriHealth Caritas District of Columbia contracting to provide the iGlucose® Cellular Diabetes Care Solution to eligible members.

Donaldson Company, Inc. (NYSE: DCI), a leading worldwide manufacturer of innovative filtration products and solutions, today broke ground on a $15 million Material Research Center at its corporate headquarters in Bloomington, Minnesota.

OncoSec Medical Incorporated (OncoSec) (NASDAQ: ONCS), a late-stage cancer biotechnology company developing intratumoral gene-delivery immunotherapies, today announced that its Board of Directors has approved a one-for-ten (1-for-10) reverse stock split of its common stock

Surgical Specialties Corporation (SSC) announced today the launch of Caliber Ophthalmics, a new business division

IDEXX Laboratories, Inc., a global leader in veterinary diagnostics, veterinary practice software and water microbiology testing, will participate in two upcoming conferences

With the release of its first quarterly results last week, NEWYOU, Inc. formerly Radiant Creations Group, Inc. came out of the new year with a name change and better than expected earnings.

Frelii Inc. announced that on May 20, 2019, it filed with the U.S. Securities and Exchange Commission its Quarterly Report on Form 10-Q for the quarter ended March 31, 2019.

Quality-adjusted progression free survival (QA-PFS) and quality-adjusted time without cancer related symptoms or toxicity (Q-TWiST) demonstrate the benefit of Rubraca maintenance treatment over placebo from a patient perspective

Merck announced that the Phase 3 KEYNOTE-119 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, as monotherapy for the second- or third-line treatment of patients with metastatic triple-negative breast cancer did not meet its pre-specified primary endpoint of superior overall survival compared to chemotherapy.